Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Express Scripts
Medtronic
Johnson and Johnson
Boehringer Ingelheim

Last Updated: May 27, 2022

Investigational Drug Information for BYL719


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for BYL719?

BYL719 is an investigational drug.

There have been 59 clinical trials for BYL719. The most recent clinical trial was a Phase 2 trial, which was initiated on July 16th 2020.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are two hundred and sixty-nine US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for BYL719
TitleSponsorPhase
SMMART Adaptive Clinical Treatment (ACT) TrialGenentech, Inc.Phase 2
SMMART Adaptive Clinical Treatment (ACT) TrialOregon Health and Science UniversityPhase 2
SMMART Adaptive Clinical Treatment (ACT) TrialOHSU Knight Cancer InstitutePhase 2

See all BYL719 clinical trials

Clinical Trial Summary for BYL719

Top disease conditions for BYL719
Top clinical trial sponsors for BYL719

See all BYL719 clinical trials

US Patents for BYL719

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BYL719 See Plans and Pricing Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) See Plans and Pricing
BYL719 See Plans and Pricing Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) See Plans and Pricing
BYL719 See Plans and Pricing Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH) See Plans and Pricing
BYL719 See Plans and Pricing Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BYL719

Drugname Country Document Number Estimated Expiration Related US Patent
BYL719 Argentina AR107432 2036-01-11 See Plans and Pricing
BYL719 Australia AU2017207268 2036-01-11 See Plans and Pricing
BYL719 Australia AU2019203280 2036-01-11 See Plans and Pricing
BYL719 Australia AU2021201018 2036-01-11 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Express Scripts
Medtronic
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.